22.40
price down icon0.09%   -0.7699
 
loading
Schlusskurs vom Vortag:
$23.17
Offen:
$23.2
24-Stunden-Volumen:
8,711
Relative Volume:
0.40
Marktkapitalisierung:
$51.38M
Einnahmen:
$5.02M
Nettoeinkommen (Verlust:
$-18.31M
KGV:
-4.9448
EPS:
-4.53
Netto-Cashflow:
$-23.40M
1W Leistung:
+16.39%
1M Leistung:
+33.43%
6M Leistung:
+65.83%
1J Leistung:
-17.85%
1-Tages-Spanne:
Value
$21.00
$23.20
1-Wochen-Bereich:
Value
$19.71
$23.20
52-Wochen-Spanne:
Value
$12.12
$29.19

Vtv Therapeutics Inc Stock (VTVT) Company Profile

Name
Firmenname
Vtv Therapeutics Inc
Name
Telefon
336-841-0300
Name
Adresse
3980 PREMIER DR, HIGH POINT, NC
Name
Mitarbeiter
23
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
VTVT's Discussions on Twitter

Vergleichen Sie VTVT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VTVT
Vtv Therapeutics Inc
21.00 51.38M 5.02M -18.31M -23.40M -4.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
498.22 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.72 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
625.08 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
256.76 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
246.81 24.70B 3.81B -644.79M -669.77M -6.24

Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2019-05-30 Eingeleitet H.C. Wainwright Buy
2018-04-10 Herabstufung Stifel Buy → Hold
2018-03-08 Eingeleitet ROTH Capital Buy
2018-02-08 Eingeleitet Northland Capital Outperform
2016-09-26 Eingeleitet H.C. Wainwright Buy
2015-09-04 Eingeleitet Canaccord Genuity Buy
2015-08-24 Eingeleitet Piper Jaffray Overweight
2015-08-24 Eingeleitet Stifel Buy
Alle ansehen

Vtv Therapeutics Inc Aktie (VTVT) Neueste Nachrichten

pulisher
Apr 22, 2025

vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga

Apr 22, 2025
pulisher
Apr 16, 2025

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World

Apr 16, 2025
pulisher
Apr 12, 2025

vTv Therapeutics Appoints Barry Brown as Interim CFO - MSN

Apr 12, 2025
pulisher
Apr 11, 2025

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at HC Wainwright - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

Q1 Earnings Forecast for VTVT Issued By HC Wainwright - Defense World

Apr 11, 2025
pulisher
Apr 09, 2025

HC Wainwright Initiates vTv Therapeutics With Buy Rating, $36 Price Target - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 09, 2025
pulisher
Apr 09, 2025

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq

Apr 09, 2025
pulisher
Apr 09, 2025

H.C. Wainwright sets $36 target for vTv Therapeutics stock By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

H.C. Wainwright sets $36 target for vTv Therapeutics stock - Investing.com

Apr 09, 2025
pulisher
Apr 04, 2025

(VTVT) Trading Advice - news.stocktradersdaily.com

Apr 04, 2025
pulisher
Mar 27, 2025

vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com - Defense World

Mar 27, 2025
pulisher
Mar 25, 2025

(VTVT) Trading Signals - news.stocktradersdaily.com

Mar 25, 2025
pulisher
Mar 21, 2025

vTv Therapeutics Inc Reports Q4 2024 EPS of -$0.55, Beating Esti - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewswire

Mar 21, 2025
pulisher
Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Nasdaq

Mar 21, 2025
pulisher
Mar 20, 2025

VTv Therapeutics: Q4 Earnings Snapshot - CTPost

Mar 20, 2025
pulisher
Mar 20, 2025

vTv Therapeutics: A New Dawn for Diabetes Treatment? - AInvest

Mar 20, 2025
pulisher
Mar 20, 2025

VTv Therapeutics: Q4 Earnings Snapshot -March 20, 2025 at 06:02 pm EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

vTv Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

FDA Greenlights vTv Diabetes Drug Trial as Cash Reserves Triple to $36.7M - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

vTv Therapeutics Inc. (VTVT) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Why Celsius Holdings Stock Popped This Week - The Globe and Mail

Mar 20, 2025
pulisher
Mar 20, 2025

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research

Mar 20, 2025
pulisher
Mar 20, 2025

Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 13.6% - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT) - Defense World

Mar 19, 2025
pulisher
Mar 17, 2025

vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup - MarketScreener

Mar 17, 2025
pulisher
Mar 17, 2025

Sector Update: Health Care Stocks Rise Late Afternoon - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sector Update: Health Care -March 17, 2025 at 03:39 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

FDA Lifts Clinical Hold, vTv Therapeutics (VTVT) Stock Surges - Stocks Telegraph

Mar 17, 2025
pulisher
Mar 17, 2025

vTv Therapeutics up after FDA lifts clinical hold on its oral diabetes treatment study - Seeking Alpha

Mar 17, 2025
pulisher
Mar 17, 2025

vTv Therapeutics resumes phase 3 diabetes trial By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

VTv Therapeutics Says FDA Lifted Clinical Hold On Cadisegliatin Program For Diabetes - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

vTv Therapeutics stock surges on FDA update By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Vtv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes; Shares Up Pre-Bell - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

vTv Therapeutics stock surges on FDA update - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

vTv Therapeutics resumes phase 3 diabetes trial - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

vTv Therapeutics Announces Resumption of CATT1 Phase 3 Trial for Cadisegliatin as Potential First Oral Adjunct Therapy for Type 1 Diabetes - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

FDA Green Light: vTv's Revolutionary Oral Diabetes Drug Back on Track with Faster Timeline - StockTitan

Mar 17, 2025
pulisher
Mar 12, 2025

3 Quality Compounders on Our Buy List - The Globe and Mail

Mar 12, 2025

Finanzdaten der Vtv Therapeutics Inc-Aktie (VTVT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
Kapitalisierung:     |  Volumen (24h):